Preserved Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Preserved Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Preserved Phase Today - Breaking & Trending Today

$CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction - Vimarsana News$

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

Published: January 29, 2022

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1

Source: businesswireindia.com

$Boehringer Ingelheim: CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction - Vimarsana News$

Boehringer Ingelheim: CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

Published: January 28, 2022

- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%1 If

Source: finanznachrichten.de

Investegate |Olink Proteomics AB Announcements | Olink Proteomics AB: Olink participates in one of the largest proteomics studies enabling new treatment options for patients with heart failure

Published: December 2, 2021

Investegate announcements from Olink Proteomics AB, Olink participates in one of the largest proteomics studies enabling new treatment options for patients with heart failure

Source: investegate.co.uk